

This high lipase formulation of Creon should allow Cystic Fibrosis patients to substantially reduce their daily capsule intake and achieve better compliance.



HIGHER DOSE, FEWER CAPSULES, HAPPIER PATIENTS

Presentation: Opaque orange yellow hard gelatin capsules containing brownish coloured enteric coated pellets of pancreatin, equivalent to:

25,000 BP units of lipase

18,000 BP units of amylaso

467 BP units of protease

Available in packs of 50. Basic NHS price £19.50

Indication: Pancreatic exocrine insufficiency

Dosage and Administration: Adults (including elderly) and children: Initially one capsule with meals, then adjust according to response

The capsules can be swallowed whole, or for ease of administration they may be opened and the granules taken with fluid or soft food, but without chewing. If the granules are mixed with food it is important that they are taken immediately, otherwise dissolution of the enteric coating may result.

contra-indicated in the early stages of acute pancreatitis. Warnings: Use in pregnancy: There is inadequate evidence of safety in use during pregnancy. The product is of porcine origin Rarely cases of hyper-uricosuria and hyper-uricaemia have been reported with very high doses of

Overdosage although not experienced until now, could precipitate meconium ileus equivalent Perianal irritation, and rarely, inflammation, could occur when large doses are used

Product Licence Number: 5727/0006

Name and Address of Licence Holder

Kali Chemie Pharma GmbH, Hans-Bockler-Allee 20, 3000, Hannover 1, Germany Further information is available from: Duphar Laboratories Limited, Gaters Hill, West End, Southampton SO3 3JD. Tel: (0703) 472281 duphar ® Registered Trade Mark

A member of the Solvay Group



Children with growth failure need the best care you can provide. And sometimes more.


The Lilly Growth Initiative is a new support programme aimed at everyone involved in the management of growth failure. The programme looks beyond the role of growth hormone therapy, to help create the right environment for growth.


It involves communicating with children at their own level, providing advice and reassurance in terms they can easily relate to. Helping parents to understand and deal with the challenges their children face. Offering practical assistance and material support to Growth Centres. Helping clinicians through educational support, growth data management, and information services.




Discover how the Lilly Growth Initiative can help you succeed in the management of growth failure. Write to: The Lilly Growth Initiative, Eli Lilly & Company Ltd., Dextra Court, Chapel Hill, Basingstoke, Hampshire RG21 2SY

The Lilly Growth Initiative. A growing involvement in child development.





Making sure Ventolin gets through to the younger generation



Ventodisks (Salbutamol BP). Abridged Prescribing Information (Please refer to full data Ventodisks (Salbutamol BP). Abridged Prescribing Information (Please refer to full data sheet before prescribing.) Uses: Treatment and prophylaxis of acute and chronic bronchospasm. Dosage and administration: Adults: 400 micrograms as single dose or three to four times daily. Children: 200 micrograms as single dose or three to four times daily. Contra-indications: Threatened abortion during first or second trimester. Hypersensitivity. Precautions: If previously effective dose lasts less than three hours, seek medical advice. Caution in patients with thyrotoxicosis. Avoid use with non-selective beta-blockers. Hypokalaemia may occur, particularly in acute severe asthma. It may be potentiated by xanthine derivatives, steroids, diuretics and hypoxia. Serum potassium levels should be monitored in such situations. Pregnancy: Avoid unnecessary use during early pregnancy. Only consider if expected benefit outweighs possible risks. Lactation: Salbutamol likely to be secreted in breast milk. Effect on neonate unknown. Balance risks against benefits. Side effects: Mild tremor, headache occur rarely. Very rarely—transient muscle cramps and hypersensitivity reactions. Potentially serious hypokalaemia may result from 82-agonist therapy. Paradoxical bronchospasm could occur—substitute alternative therapy. Presentation and Basic NHS cost: Pack of 14 Ventodisks each containing 8 x 200 micrograms Salbutamol BP (as sulphate)—light blue or 8 x 400 micrograms Salbutamol BP (as sulphate)—dark blue, together with a Ventolin Diskhaler. For inhalation. £7-11 and £12-02. Refill pack of 14 x 8 Ventodisks only. 200 micrograms, £6-54; 400 micrograms, £11-45.

Product licence numbers: Ventodisks 200 micrograms 0045/0134, Ventodisks 400 micrograms 0045/0135.



PRESCRIBING INFORMATION Presentation TILADE Mint is a metered dose pressurised aerosol inhaler which delivers 56 puffs, each containing 2mg Nedocromil sodium. Indications TILADE Mint is indicated for the preventive treatment of reversible obstructive airways disease, including ashma and ashmatic bronchitis. Dosage and Administration Adults and children over 12 years of age: 2 puffs (4mg Nedocromil sodium) to be inhaled twice daily. If necessary, dosage may be increased to 2 puffs four times daily.

Children under 12 years of age: it is recommended that TILADE Mint should not be used since it is still under investigation in this age group. TILADE Mint is intended for regular daily usage and should not be used for relief of symptoms in an acute attack. Side effects, precautions and contra-indications Few side effects have been reported, principally headache and nausea. The mint flavour has been added to mask any bitter taste of the drug. Caution should be exercised in the use of TILADE Mint in pregnant or lactating

women. There are no specific contraindications. <u>Basic NHS Cost</u> 2 x 56 actuations £18.65. <u>PL Number:</u> 0113/0140. Further information is available on request. Registered Trade Mark of the Manufacturer. Fisons plc - Pharmaceutical Division, 12 Derby Road, Loughborough, leicestershire LE11 OBB

13/0140. quest nufacturer. Pharmaceuticals









The importance of palatability is gaining weight.

Any hypoallergenic formula for the treatment of chronic diarrhoea and food intolerances is only as good as it tastes. Because for a baby to readily accept the prescription it must first be palatable.


Prejomin not only tastes better, it's also completely free of lactose and milk protein residues. This makes it suitable for even more hypersensitive patients.

And because Prejomin contains a carefully balanced mixture of nutrients, it helps the baby to regain weight quickly. And that's something we're sure that you and your patients will be more than happy to swallow.

Prejomin. The palatable solution to the dietetic management of chronic diarrheoa and food intolerances.







Prescribing Information Presentation: Epanutin Capsules, 25mg, 50mg, 100mg or 300mg phenytoin sodium Ph Eur. Epanutin Suspension 30mg/5ml phenytoin BP. Epanutin Infatabs, 50mg phenytoin BP. Indications: Grand mal epilepsy, temporal lobe seizures and certain other convulsive states. Dosage: Usual maintenance dosages: Infants and children: 4-8mg/kg, up to a maximum of 300mg daily. Adults: 200-500mg daily in single or divided doses. Exceptionally, a daily dose outside this range may be indicated. Dosage recommendations are only guidelines and should be titrated for individual patients. Chew Infatabs, Titrate dosage gradually. Plasma level monitoring is advisable. Equal doses of Infatabs and capsules may not give equivalent blood levels. Contra-indications and precautions: Hypersensitivity to hydantoins. Use in pregnancy and lactation. Liver dysfunction. Replacement of or with other anticonvulsant therapy should be gradual. Plasma levels may be altered by other drugs - see literature. Side-effects: Transient GI and CNS disturbances subsiding with continued use. Allergic phenomena (e.g. rash, lupus erythematosus, hepatitis, lymphadenopathy) may occur. Haematological disorders, gingival hypertrophy, hirsutism and excessive motor activity have been reported. Nystagmus

with diplopia and ataxia indicates that dosage should be reduced. **Legal category:** POM. **Product Licence Numbers:** Capsules, 25, 50, 100mg/18/0112, 18/5079, 18/5080, 300mg, 18/0158. Suspension 18/5106. Infatabs 18/0069. **Basic NHS cost:** Capsules, 25mg 500 £9.82; 50mg 500 £10.02; 100mg 500 £12.77;1000 £24.15; 300mg 100 £7.66; Infatabs 100 £5.49. Suspension 500ml £3.56 Further information is available from Parke-Davis Research Laboratories,

Further information is available from Parke-Davis Research Laboratories Lambert Court, Chestnut Avenue, Eastleigh, Hampshire SO5 3ZQ. Telephone: (0703) 620500.

References: (0703)

1. Data on file, Parke-Davis Research Laboratories.

PARKE-DAVIS DESERTORES

© Parke-Davis Research Laboratories 1992

* Trade mark

A118-UK-Mar92

For all professionals concerned with child health and disease...

Molecular Genetics of Pediatric Solid Tumors Basic Concepts and Recent Advances

Edited by G P Tonini, R Sansone and C J Thiele

This book describes the most recent perspectives and approaches including cytogenetics, cellular oncogenes, tumor suppressor genes and molecular epidemiology and also focuses on specific pathologies, with particular attention given to molecular studies generating hypotheses on etiopathogenesis and disease progression mechanisms.

1992 • 382 pp. • Hardcover • ISBN 3-7186-5080-0 • List Price: £50.00 • SAS Price: £25.00*

Monographs in Clinical Pediatrics

Series Editor: P Lanzkowsky • Series ISSN 1044-4882

Volume 1

Essential Pediatric Dermatology

By J A Keipert

A practical reference guide for diagnosing and treating dermatological disorders, with more than 200 illustrations, mostly in colour.

1990 • 221 pp. • Hardcover • ISBN 3-7186-0505-8 • List Price: £70.00 • SAS Price: £32.00*

Volume 2

Infectious Disease in Pregnancy and the Newborn Infant

By G L Gilbert

This comprehensive and up-to-date single author text contains 23 chapters and coherently covers all major congenital and perinatally-transmitted infections plus many other topics.

1991 • 618 pp. • Hardcover • ISBN 3-7186-5069-X • List Price: £72.00 • Softcover • ISBN 3-7186-5174-2 • List Price: £38.00

Volume 3

Pediatric Neuro-oncology New Trends in Clinical Research

Edited by R J Packer, W A Bleyer and C Pochedly

Partial Contents: The Impact of Monoclonal Antibody
Studies on Changing Nosology and Biological Concepts of
Brain Tumors • Stimulation Mapping and Recording
Techniques Used During Brain Tumor Surgery • Role of
Chemotherapy in the Management of Childhood
Medulloblastoma/Primitive Neuroectodermal Tumor •
Chemotherapeutic Strategies for High-Grade
Astrocytomas of Childhood

1992 • 315 pp. • Hardcover • ISBN 3-7186-0524-4 • List Price: £46.00 • SAS Price: £28.00*

*SAS Price is available to individuals who join the Science and Arts Society (SAS) book club! A lifetime membership fee of £5.00 entitles members to these and many other titles at substantial discounts. SAS members do not pay postage and handling charges. All other orders must include £3.00 per book for postage and handling. Prices are subject to change without notice.

Volume 4

Atherosclerosis Prevention Identification and Treatment of the Child with High Cholesterol

Edited by M S Jacobson

Partial Contents: The Epidemiologic Basis for the Prevention of Pediatric Atherosclerosis • Smoking and Atherosclerosis • Essentials of Office Management of Atherosclerosis Prevention: Screening, Classification of Risk, Treatment and Follow-Up • Appendix: Summary of the new guidelines from the report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents of the National Cholesterol Education Projection (NCEP) 1992 • 164 pp. • Hardcover • ISBN 3-7186-5121-1 • List Price: £34.00 • SAS Price: £17.00*

Volume 5

Feeding Problems and Eating Disorders in Children and Adolescents

Edited by P J Cooper and A Stein

Partial Contents: The Nature and Consequences of Feeding Problems in Infants • The Nature and Management of Eating Problems in Pre-School Children • Anorexia Nervosa of Early Onset and Its Impact on Puberty • Family Factors in Eating Disorders • Intensive Hospital Treatment for Anorexia Nervosa and Bulimia Nervosa

1992 • 205 pp. • Hardcover • ISBN 3-7186-5158-0 • List Price: £50.00 • Softcover • ISBN 3-7186-5166-1 • List Price: £20.00

Harwood Academic Publishers, c/o STBS, PO Box 90, Reading, Berkshire RG1 8JL, UK (STBS - Distributors for Harwood Academic Publishers)





A world of difference

More and more patients with uncontrolled epilepsy are able to face the world thanks to the efficacy of SABRIL.

Many have become seizure free for the first time and approximately half can benefit from a > 50% reduction in their seizures.¹



Controlling seizures, changing lives

tion: White, tablets with a brea line marked SABRIL, each contr ning 500mg vigebatrin.

indications: Treatment of epilepsy not controlled by other antiepileptic drug and Administration: Oral administration once or twice daily added to

is: Recommended starting dose 2g/day, Increased or decreased in 0.5g or 1.0g increments depending upon clinical response and tolerability. Maximum 4g/day. There is no direct correlation een plasma concentration and efficacy

a disease. It is a support of the su

10-15kg 0.5 to 1g/day

15-30k 1.0-1.5g/da 1.5-3g/day

>50kg 2-4g/day
Infants with West syndrome may require doses of 100mg/kg/day or higher
Elderly: Consider dose reduction in patients with impaired renal function.

autions: Abrupt withdrawal may lead to rebound seizures. Caution in patients with history of psychosis or behavioural problems. Caution in elderly patients, particularly creatinine cle 60mi/min. Reduce dose and monitor closely for adverse even

rin causes intramyelinic cedema in the brain white matter tracts of animals but there is no evidence of this in man. However, monitor patients for neurological changes. See the full

Effects on driving ability: Drowsiness has been seen and patients should be warned.

Side effects: Are mainly CNS related. Aggression and psychosis have been reported and a previous history of psychosis or a behavioural problem appears to be a predisposing factor. Other reported events: drowsiness and fatigue, dizziness, nervousness, irritability, depression, headache and less commonly confusion, memory disturbance and vision complaints; also weight gain and minor gastrointestinal side-effects. Also in children excitation and agitation. Some patients may experience an increase in selzure frequency with vigabatrin, particularly those with mycolonic selzures. Tests have not revealed evidence of neurotoxicity in humans. Lab data do not indicate renal or hepatic toxicity. Decreases in SGOT and SGPT have been observed. Chronic treatment may lead to a slight

tions: Are unlikely. A gradual reduction of about 20% in plasma phenytoin concentration has been observed.

No clinically significant interactions with carbamazepine, phenobarbitone or sodium valproate.

Cetegory: POM
age Quantities: Blister strips of 10 in cartons of 100.

Product Licence Number: PL 4425/0098

NHS Price: £46.00

Date of Preparation: January 1992.

You must refer to the full prescribing information before administering Sabril. Further information including full product data sheet is available from the Licence Holder: Marion Merrell Dow Ltd., Lakeside House, Stockley Park, Unbridge, Middlesex. UB11 1BE.


1. Murriford JP.Br J Clin Pract 1988; 42 (Suppl 61): 7-9

--5



MARION MERRELL DOW LTD.





UK £6.95; Abroad £8.00 (BMA members £6.45 or £7.50) including postage, by air abroad

ORDER YOUR COPY


NOW

An excellent beginner's guide

The extraordinary technical developments in molecular biology over the past few years, and the equally rapid advances in understanding of cell biology, will almost certainly result in far reaching changes in medical research and practice. In this collection of articles experts in molecular and cell biology provide the background information to give clinicians an insight into the way in which the medical sciences may be moving over the next few years and into the exciting possibilities opening up for the treatment of genetic disorders, cancer, and the common illnesses of Western society such as degenerative vascular disease and diabetes.

Available from: BRITISH MEDICAL JOURNAL, PO Box 295, London WCIH 9TE, medical booksellers or the BMJ bookshop in BMA House	I enclosePlease make cheques payable to British Medical Journal
	Debit my credit card (please tick box)
Please send mecopy/ies of	□ Visa □ American Express □ Mastercard
BASIC MOLECULAR & CELL BIOLOGY	Card No
NAME	Card expiry date
ADDRESS	Signature
	BMA Membership No
POSTCODE	☐ Please send me a book catalogue

While you're trying to make it better, make it bearable.





Prescribing information: Uses Nausea and vomiting due to chemotherapy or radiotherapy. Dosage Emetogenic chemotherapy and radiotherapy: Either, 8mg i.v. as a slow injection immediately before treatment, or 8mg orally 1 to 2 hours before treatment, followed by 8mg orally twelve-hourly. To protect against delayed emesis, Zofran should be continued orally, 8mg twice daily for up to 5 days. Highly emetogenic chemotherapy: A single dose of 8mg i.v. as a slow injection immediately before chemotherapy, followed by 8mg orally twice daily for up to 5 days to protect against delayed emesis. The efficacy of Zofran over the first 24 hours of highly emetogenic chemotherapy may be enhanced by the addition of a single i.v. dose of 20mg dexamethasone immediately before treatment. Alternatively, higher doses of Zofran may be beneficial, up to 32mg depending on the severity of the emetogenic challenge. Children: A single i.v. dose of 5mg/m² immediately before chemotherapy, followed by 4mg orally twelve-hourly for up to 5 days. Elderly and patients with renal impairment: No alteration of dosage, dosing frequency or route of administration is required over 65 years or with renal impairment. Patients with hepatic impairment: In potients with moderate or severe hepatic impairment, a total daily dosage of 8mg should not be exceeded. Contra-

indications Hypersensitivity to components. **Precautions** Pregnancy or loctation. **Side effects** Headache, constipation, a warm or flushing sensation in the head 'or epigastrium. Occasional transient rises in aminotransferases. Rare, immediate hypersensitivity reactions (see data sheet). **Presentations** Zofran Injection ampoules containing 4mg andonsetron in 2ml aqueous solution or 8mg andonsetron in 4ml aqueous solution (Product licence number 0004/0375, 4mg x 5 ampoules £75). Zofran 4mg Tablets each containing 4mg andansetron (Product licence number 0004/0376, 4mg x 30 tablets £187-50). Zofran 8mg Tablets each containing 8mg andansetron (Product licence number 0004/0377, 8mg x 10 tablets £990). **Product licence holder** Glaxo Operations U.K. Limited, Greenford, Middlesex UB6 OHE. Zofran is a Glaxo trade mark. Further information is available on request from: Glaxo Laboratories Limited, Stockley Park West, Uxbridge, Middlesex UB11 IBIT. Tel: 081-990 9444.

GROWTH RESEARCH GRANTS

To continue support for growth research in the UK and Eire The Lilly Growth Team are pleased to announce that they will be awarding grants.

All applications must be received by 1 September 1992 and will be assessed by an independent scientific panel.

The individual awards of up to £10,000 will be made in October 1992.

For further information or an application form please contact:

Dr D M Anderson
Clinical Research Physician
LILLY INDUSTRIES LIMITED
Dextra Court
Chapel Hill
Basingstoke
Hants RG21 2SY

Tel: 0256 473241

INSTITUTE OF CHILD HEALTH (University of London)

PULMONARY PROBLEMS IN THE PERINATAL PERIOD AND THEIR SEQUELAE 6th-7th July 1992

This course will review the morphological and physiological aspects of both normal and abnormal growth and development of the respiratory system during fetal life and infancy. The immediate and long term sequelae of naturally occuring environmental and iatrogenic insults will be discussed with respect to both lung structure and function. Methods of assessing lung function in infancy will be described and opportunities provided for informal demonstrations of current techniques in the laboratory.

The fee is £120 (including lunch)

RESPIRATORY DISEASE IN CHILDHOOD: RECENT ADVANCES 8th-9th July 1992

This course will review the investigation and management of a number of respiratory conditions including asthma, cystic fibrosis, adult RDS, chronic lung diseases in the newborn and in the immunosuppressed. The effects of gastro-oesophageal reflux will be reviewed as will the current situation in heart-lung transplantation.

The fee is £120 (including lunch)

For further details please contact the:-

Short Courses Office Institute of Child Health 30 Guilford Street London WC1N 1EH

Tel: 071 829 8692 (direct line)

INSTITUTE OF CHILD HEALTH

(University of London)
Growth for the Nineties
20–21 July 1992

This course will cover the major problems in growth and development over the next decade. In particular the main themes will include: Infant nutrition and growth; modern management of short stature; disorders of puberty; and the impact of chronic disease on growth and puberty.

Course fee: £120 including lunch and refreshments

For further information and a registration form please contact:

Short Courses Office, Institute of Child Health 30 Guilford Street, London WC1N 1EH

Tel: 071 829 8692 (direct line) Fax: 071 831 0488

European Journal of

Pediatrics

Incorporating
Acta Paediatrica Belgica
and
Helvetica Paediatrica Acta

Volume 151 No. 4 1992

Editorial note 241

The pioneers of pediatric medicine 242

Review

Molecular hybridization techniques in current diagnosis of chronic hepatitis B in childhood

S. Wirth, B. Zabel 243

Cardiology

Transient cardiac constriction following purulent pericarditis

A. Allaria, D. Michelli, H. Capelli, G. Berri, D. Gutierrez **250**

Dermatology

Lethal junctional epidermolysis bullosa with normal expression of BM 600 and antro-pyloric atresia: a new variant of junctional epidermolysis bullosa? J.P. Lacour, P. Hoffmann, F. Bastiani-Griffet, P. Boutte, A. Pisani, J. P. Ortonne 252

Endocrinology

Development of height and weight in children with diabetes mellitus: report on two prospective multicentre studies, one cross-sectional, one longitudinal A.Thon, E. Heinze, K.-D. Feilen, R.W. Holl, H. Schmidt, S. Koletzko, U. Wendel, J. Nothjunge 258

Diagnostic value of growth hormonereleasing hormone test in children and adolescents with idiopathic growth hormone deficiency

T. Arrigo, F. Martino, F. Lombardo, N. Laforgia, A. Acquafredda, R. Russo, L. Cavallo, F. De Luca **263** The association of hypopituitarism with small pituitary, invisible pituitary stalk, type 1 Arnold-Chiari malformation, and syringomyelia in seven patients born in breech position: a further proof of birth injury theory on the pathogenesis of "idiopathic hypopituitarism" K. Fujita, N. Matsuo, O. Mori, N. Koda,

K. Fujita, N. Matsuo, O. Mori, N. Koda E. Mukai, Y. Okabe, N. Shirakawa, S. Tamai, Y. Itagane, I. Hibi **266**

Hematology/Oncology

latrogenic IgG₂ deficiency in a leukaemic child

A.W. de Boer, G.A.M. de Vaan, C.M.R. Weemaes, J.A.J.M. Bakkeren 271

Immunology/Allergology

IgG subclass deficiency in children with recurrent bronchitis

F. De Baets, J. Kint, R. Pauwels, J. Leroy 274

Cytochrome b positive X-linked chronic granulomatous disease: a normal cell surface expression of cytochrome b H. Azuma, H. Oomi, D. Ueda, K. Sasaki, Y. Makita, K. Tomizawa, Y. Sakiyama, K. Fujita, H. Yoshioka, A. Okuno 279

Medical genetics

Spontaneous growth in Turner syndrome: evidence for a minor pubertal growth spurt

G. Haeusler, M. Schemper, H. Frisch, P. Blümel, K. Schmitt, E. Plöchl 283

A family with one child with acrocallosal syndrome, one child with anencephaly-polydactyly, and parental consanguinity S. Cataltepe, E. Tuncbilek 288

Defective monocyte oxidative metabolism in a child with Smith-Lemli-Opitz syndrome

G. Zahle Østergaard, H. Nielsen, B. Friis 291

Neonatology

The relationship of fluid restriction during the 1st month of life to the occurrence and severity of bronchopulmonary dysplasia in low birth weight infants: a 1-year radiological follow up O.K.T. Tammela, F.P. Lanning,

O. K.T. Tammela, F. P. Lanning, M. E. Koivisto **295**

Neonatal intestinal perforation due to congenital defects in the intestinal muscularis

S. Izraeli, E. Freud, C. Mor, A. Litwin, M. Zer, P. Merlob **300**

Intra-uterine long bone growth in small-for-gestational-age infants J. Palacios, S. Rodríguez, J. I. Rodríguez 304

Asymptomatic urinary tract infection in childhood

I. Nebigil, N. Tümer 308

Letters to the editors

Plasma exchange for fulminant Wilson disease

J. Sarles, P. Lefevre, G. Picon 310

Beta-mannosidosis and ethanolaminuria in a female patient

H. Wijburg, J. de Jong, R. Wevers, J. Bakkeren, F. Trijbels, R. Sengers **311**

Dignity of the perinatal optimality score of Prechtl

H. Manzke 311

Branchio-oculo-facial syndrome. Report of a new case with agenesis of cerebellar vermis

D. Mazzone, A. Milana, C. Carpinato 312

Haemorrhagic cystitis and urinary retention in Henoch-Schönlein purpura S.J.Allen, A.Sprigg, D.C.Davidson 312

3-Methylglutaconic aciduria in a patient with a disturbed mitochondrial energy metabolism

J. A. J. M. Bakkeren, R. C. A. Sengers, W. Ruitenbeek, J. M. F. Trijbels 313

Reply

L. Thun-Hohenstein, R. H. Largo 313

Urinary N-acetyl-β-p-glucosaminidase activity in a girl with distal renal tubular acidosis

E. Ring, W. Erwa, M. Haim-Kuttnig 314

News for the practitioner 315

Indexed in Current Contents



Springer International

Subscription information

Volume 150 (12 issues) will appear in 1991. Information about obtaining back volumes and microform editions available upon request.


North America. Annual subscription rate: approx. US \$ 1060.00 (single issue price approx. \$ 102.00), including carriage charges. Subscriptions are entered with prepayment only.

Orders should be addressed to: Springer-Verlag New York Inc. Service Center Secaucus 44 Hartz Way Secaucus, NJ 07094, USA Tel. (201) 348-4033

Tel. (201) 348-4033 Telex 023125994 FAX (201) 348-4505

All other countries. Annual subscription rate: DM 1598.00 plus carriage charges; Federal Republic of Germany: DM 27.61 incl. value added tax; all other countries: DM 60.60 except for the following countries to which SAL delivery (Surface Airmail Lifted) is mandatory: Japan DM 125.40, India DM 96.60, Australia! New Zealand DM 141.00. Airmail delivery to all other countries is available upon request. Volume price: DM 1598.00, single issue price: DM 159.80 plus carriage charges. Subscriptions can either be placed via a bookdealer or sent directly to:

Springer-Verlag Heidelberger Platz 3, 1000 Berlin 33, FRG Tel. (0)30/8207-0, Telex 183319 FAX (0)30/8214091



NovoPen® II

Already a design award winner,1 NovoPen II has recently received even more attention to detail. The latest model incorporates an easy grip on the dosage dial and a smoother action on the locking ring a safety feature unique to NovoPen II. The stylish new appearance completes the latest design improvements making NovoPen II even bener than before.

PenMix® Penfill® cartridges

Biphasic Isophane Insulin Injection,
Human Insulin (pyr).

The first premixed insulin in a Penfill was PenMix 30/70 Penfill, in a ratio well suited to the majority of diabetics using premixed insulins.

Penfill®

The introduction of four additional mixtures makes PenMix® Penfill® the widest range of premixed insulins available in

cartridges, and means that even more diabetics could be using NovoPen II.

enMix® 10/90 Penfill® ?enMix® 20/80 enMix* 40/60

enMix® 50/50

New NovoFine® needles

The new NovoFine needles for NovoPen II are very fine 28-gauge needles for a virtually painless injection.2

Novopen® III
FOR MIXTURES TOO

NOVO NORDISK A/S Coperhagen, Denmark

Parket soft motor & could be free NOVO NORDISK PHARMACEUTICALS LTD Novo Nordisk House, Broadfield Parts, Brighton Road, Peans Pottage, Conviley, Telephone: (0203) 613355

Est of Most Post a